egfr mutations lung cancer: correlation clinical response gefitinib therapy 
receptor tyrosine kinase genes sequenced non small cell lung cancer nsclc matched normal tissue somatic mutations epidermal growth factor receptor gene egfr found unselected tumors japan united states treatment egfr kinase inhibitor gefitinib iressa causes tumor regression patients nsclc frequently japan egfr mutations found additional lung cancer samples u s patients responded gefitinib therapy lung adenocarcinoma cell line hypersensitive growth inhibition gefitinib gefitinib-insensitive tumors cell lines results suggest egfr mutations may predict sensitivity gefitinib 
